The Ready To Use Platform Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is supplied under the platform designation RTU-PHA-API-OMNI-01. Subgrades are assigned by intended unit operation: RTU-DC-01 for direct compression tablets, RTU-CF-01 for two-piece hard capsule filling, RTU-GR-01 for granule and sachet manufacture, and RTU-SI-01 for sterile injectable processing. The platform is an active pharmaceutical ingredient in a physically controlled form, not a finished dosage form and not a pre-blended excipient system. Release testing follows current pharmacopoeial monographs where available and applies ICH Q3A, ICH Q3C, ICH Q3D, and ICH Q6A decision-tree controls when a monograph does not cover the specific physical grade. Each lot is accompanied by a certificate of analysis stating assay, related substances, residual solvents, water content, particle-size distribution, bulk density, tapped density, and, for injectable subgrades, endotoxin and bioburden.

The direct compression subgrade RTU-DC-01 is used after dry blending with a disintegrant, a filler, and a lubricant. It is released with a laser diffraction D50 between 90 µm and 150 µm, D10 not less than 30 µm, and D90 not more than 250 µm using a dry dispersion method aligned with USP <429>. Bulk density is specified between 0.45 g/mL and 0.65 g/mL and tapped density between 0.55 g/mL and 0.80 g/mL per USP <616>. Water content by Karl Fischer titration is not more than 0.5% w/w unless a lower limit is required for moisture-sensitive formulations. On rotary tablet presses with 45-station or larger turrets, powders with a Carr index above 30 tend to produce variable die fill and require higher paddle speeds in the feed frame; the solid oral subgrades are therefore released with a Carr index target not exceeding 25 and a Hausner ratio not exceeding 1.35. The compression step is normally run on a force-controlled rotary press at main compression forces from 8 kN to 18 kN for a 10 mm round standard concave tooling, depending on tablet weight and formulation; precompression force is typically set between 2 kN and 5 kN. The actual force must be established by the dosage-form manufacturer because compaction behaviour depends on excipient grade, punch tip geometry, and press speed.

What Constitutes a Ready-to-Use Platform Grade Versus Monographs for Unprocessed API?

A conventional monograph-compliant API lot may meet chemical purity but may be discharged from the crystallizer with a broad particle-size distribution, a high fraction of fines, or a D90 exceeding 500 µm. In that condition, the lot is not directly suitable for dry blending with low-dose active ingredients because segregation, poor flow, and content uniformity failures can occur. The platform grade is manufactured or conditioned to a defined physical state, and the physical specification is part of the release certificate. The chemical monograph remains applicable; the platform adds a physical specification and, for injectable use, a microbiological specification. The addition of a physical specification does not alter the API’s synthetic route, salt form, polymorphic form, or impurity profile unless the manufacturer has filed a change to the regulatory dossier.

When Particle Size and Flow Must Align with USP <1174> Powder Flow Classification

For tablet dosage forms, the relevant flow classification under USP <1174> is not a single number but a set of scales based on orifice flow, angle of repose, compressibility index, and Hausner ratio. The platform subgrades for solid oral use are specified against compressibility index and Hausner ratio because these are practical for release testing. RTU-DC-01 and RTU-CF-01 are controlled to a compressibility index no greater than 25, corresponding to passable-to-good flow. RTU-GR-01 granules are controlled to a compressibility index no greater than 20 after drying. Angle of repose is not used as a release test because it is significantly affected by sampling technique and equipment geometry; however, process characterisation batches have shown angle of repose values in the range of 30° to 40° for direct compression subgrades. The controlled particle-size distribution reduces the need for dry milling, which can generate fines and increase dust exposure.

The physical specification is intended to match the constraints of high-speed capsule machines and tablet presses. On a tamping-pin encapsulator running at 30,000 to 80,000 capsules per hour, die-hole fill consistency depends on powder bed depth, tamping pin compression, and particle-size distribution. The RTU-CF-01 subgrade is released with D50 between 100 µm and 180 µm, D90 not more than 300 µm, and the same compressibility index and Hausner ratio limits. This allows transfer from intermediate bulk containers to machine hoppers without pre-sieving. The use of sodium stearyl fumarate or magnesium stearate as a lubricant in a low-shear tumble blender for 2 to 5 minutes at 15 to 25 rpm is typical of process development batches; extended lubrication above 10 minutes may cause over-lubrication and reduced tablet hardness in direct compression. Published data for a given API in this platform configuration should be generated through design-of-experiment batches rather than taken as a universal processing guarantee.

The RTU-GR-01 subgrade is supplied as pre-screened granules with D50 between 180 µm and 350 µm, a fraction above 850 µm no greater than 10%, and friability no greater than 1.0% when tested according to a validated tumbling friability method. This fraction specification is relevant for high-shear wet granulation and fluid-bed granulation because oversized granules produce poor die fill and visible surface defects on tablets. In high-shear granulation, the subgrade may be combined with a binder solution in a 600 L high-shear mixer using an impeller tip speed of 5 to 8 m/s and a chopper speed of 1,500 to 3,000 rpm, followed by fluid-bed drying to a moisture content between 1.0% and 2.0% w/w. The resulting granules should be milled through a 1.0 mm to 1.5 mm screen before final blending. For sachet filling, the RTU-GR-01 granule may be filled directly into aluminium or polyethylene laminate sachets using auger or volumetric cup fillers at fill weights from 500 mg to 5,000 mg; the fill weight range must be validated for the specific machine and granule flow. Sachet stability is dependent on seal integrity; package leak testing per ASTM D3078 should be included in packaging validation.

Sterile Injectable Subgrades and Aseptic Processing Boundaries

RTU-SI-01 is supplied as a low-bioburden, endotoxin-controlled powder for reconstitution or dissolution into injectable formulations. The material is not automatically sterile; terminal sterilization by autoclave, gamma irradiation, or ethylene oxide must be selected based on the API’s thermal and radiolytic stability. For aseptic processing, the subgrade is released with bioburden no greater than 10 CFU/g and endotoxin no greater than 0.25 EU/mg, measured by USP <85>. Reconstituted solutions must meet the clarity criteria of USP <790> for solution dosage forms. If the formulated solution is intended for fill-finish, a 0.22 µm sterilizing-grade filter is used before filling, and the filled product is tested for container closure integrity per USP <1207>. For injectable suspensions, particle size after dispersion should be validated by the dosage-form manufacturer using wet laser diffraction or light obscuration; the API subgrade can be micronized to a D90 no greater than 10 µm where the route of administration requires reduced particle size for syringeability and tissue tolerability.

For parenteral use, the API must be compatible with the selected vehicle. pH adjustment, tonicity agents, and antioxidant systems must be evaluated in formulation development because the platform grade itself does not address chemical degradation in solution. If the solution is to be lyophilized, the freeze-drying cycle is developed around the final formulation, not the API platform alone. Terminal sterilization by saturated steam is not appropriate for hydrolytically labile APIs; in such cases, aseptic processing from low-bioburden powder is used, but this shifts the sterility assurance burden to the fill-finish line and requires media-fill validation according to current GMP expectations.

Contrasting Platform-Grade Material with Unprocessed API and Pre-Blended Intermediates

The operational difference between this platform and an unprocessed API is measured in the number of in-house processing steps. An unprocessed API lot may require dry milling, sieving, blending with flow aid, and granulation before encapsulation or compression. The platform subgrades are released with particle-size and flow specifications that remove dry milling and sieving for many solid oral processes. Compared with a pre-blended intermediate that includes diluents, disintegrants, or binders, this platform contains no added excipients. The dosage-form manufacturer retains full control over formulation composition, lubricant selection, and excipient compatibility. That distinction is important for regulatory dossiers because pre-blended intermediates may cross the line between API and finished product under ICH Q7 and regional GMP definitions. This platform is controlled as an API and is released under API GMP.

In practice, the difference appears in the equipment bill of a non-sterile oral solid facility. A conventional API powder with D90 above 500 µm may require a cone mill or hammer mill, a rotary sieve, and dust containment before it can enter a bin blender. The RTU-DC-01 and RTU-CF-01 subgrades can be discharged from the drum into a free-fall IBC or hopper and then blended directly with excipients. This reduces the number of operator exposure points and the in-house cleaning burden, but it does not remove the need for blending validation, content uniformity testing, or dissolution testing.

What Operational Boundaries and Incompatibilities Apply to Multi-Route Platform Use?

The platform should not be exposed to open ambient conditions above 60% relative humidity for transfer times exceeding 8 hours unless the specific subgrade has been demonstrated to be non-hygroscopic. Moisture uptake at high humidity can alter flow and particle agglomeration, particularly in direct compression and capsule-filling subgrades. Storage should be in double polyethylene bags inside an HDPE drum at 15°C to 25°C unless the API requires cold-chain storage. Oxidatively sensitive APIs should be packaged under nitrogen or argon and protected from light in amber glass or opaque polypropylene containers. The platform is not intended to replace compatibility studies with selected excipients; binary compatibility testing remains necessary before full-scale blending. For sterile injectable use, the API subgrade must be compatible with the selected terminal sterilization method. If autoclaving causes hydrolysis, aseptic processing from a low-bioburden powder is used, but this shifts the sterility assurance burden to the fill-finish line and requires media-fill validation according to current GMP expectations. Published data for specific new chemical entities in this platform configuration is limited; therefore, process validation batches and stability studies must be generated by the dosage-form manufacturer before commercial release.